improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric organization (APA) annual assembly in San Diego. [click link for full article]
12-Month Study Demonstrated Tolerability And Efficacy Of Daytrana For ADHD
Posted by admin in Health on 05 30th, 2007 | no responses
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANA™ (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided meaningful
Original post by admin
Leave a Reply
